Track topics on Twitter Track topics that are important to you
Ovid Therapeutics (NASDAQ:OVID) has announced its financial results for Q3 2019 ended September 30. As quoted in the press release: “2020 is poised to be a transformational year for Ovid. We expect multiple clinical trial data readouts across our pipeline including topline results from our pivotal Phase 3 NEPTUNE trial in Angelman syndrome,” said Jeremy … Continued
Original Article: Ovid Therapeutics Reports Q3 Financial ResultsNEXT ARTICLE
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...